Article

Dual targeting of RET and SRC synergizes in RET fusion-positive cancer cells

2025-04-26

Abstract excerpt

RET fusions drive subsets of non-small cell lung cancer (NSCLC) and papillary thyroid carcinoma (PTC). Despite new selective RET tyrosine kinase inhibitors (TKIs) resistance usually occurs and is often driven by RET -independent bypass mechanisms. Previous studies have implied crosstalk between RET and SRC, but the anti-cancer effects of targeting SRC combined with selective RET TKIs and the underlying molecular...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 70d326be-2798-5ca7-95fd-a34cd58e7ba4
DOI: 10.1101/2025.04.24.650465

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Dual targeting of RET and SRC synergizes in RET fusion-positive cancer cellsDOI 10.1101/2025.04.24.650465Read

RET Inhibitors in RET Fusion-Positive Lung Cancers: Past, Present, and Future.Semantic proximity Read

RET signaling pathway and RET inhibitors in human cancerSemantic proximity Read

RET Signaling Pathway in Human Cancer: Oncogenic Mechanisms, Selective Inhibitors, and Emerging Resistance Strategies.Semantic proximity Read

Targeting RET alterations in non-small cell lung cancer.Semantic proximity Read

Resistance to RET-Inhibition in RET-Rearranged NSCLC Is Mediated By Reactivation of RAS/MAPK Signaling.Semantic proximity Read

The Mitogen-Activated Protein Kinase Pathway Facilitates Resistance to the Src Inhibitor Dasatinib in Thyroid Cancer.Semantic proximity Read

Targeting RET alterations in cancer: Recent progress and future directions.Semantic proximity Read

Selpercatinib for lung and thyroid cancers with RET gene mutations or fusions.Semantic proximity Read

State-of-the-Art Strategies for Targeting RET -Dependent CancersSemantic proximity Read

Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor modelsSemantic proximity Read

RET kinase inhibitors for the treatment of RET-altered thyroid cancers: Current knowledge and future directions.Semantic proximity Read

Apatinib inhibits cellular invasion and migration by fusion kinase KIF5B-RET via suppressing RET/Src signaling pathwaySemantic proximity Read